Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1507 of 5804
-
Can a smart scale and app tame childhood obesity?
Disease control Recruiting nowEvira is a digital support system newly developed for treatment of childhood obesity. Through daily weighings at home using a special scale together with a message function in the Evira application, enabling fast and easy communication with the clinic, parents and the clinicians …
Phase: NA • Sponsor: Karolinska Institutet • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Can a 14-Day Anti-Inflammatory shot stop heart failure after a heart attack?
Disease control OngoingPatients who have a heart attack are at high risk for future development of heart failure ('weakening of the heart'). The researchers believe that the reaction of the heart muscle to injury (inflammation) during a heart attack may be contributing to the risk of heart failure. The…
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Targeted pill shows promise for rare genetic cancers
Disease control CompletedThis study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF) mutations in the Patched-1 (PTCH1) gene. Stage 1 of t…
Phase: PHASE2 • Sponsor: Endeavor Biomedicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Cholesterol control may cut stroke risk in brain artery disease
Disease control Recruiting nowsICASBLM is a prospective controlled trial, to asses the impact of improving blood lipid management on clinical outcome of moderate to severe symptomatic intracranial atherosclerotic stenosis patients (LDL-C\>1.8mmol/L) without endovascular therapy.
Phase: NA • Sponsor: Nanjing First Hospital, Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for leukemia patients Who've run out of options
Disease control Recruiting nowThe purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in patients with chronic myeloid leukemia with and without T315I mutations in patients who are relapsed, refractory or intolerant to TK…
Phase: PHASE1 • Sponsor: Enliven Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
500 stroke patients enrolled to uncover hidden clues in blood and brain scans
Knowledge-focused Recruiting nowIschemic stroke is the first cause of acquired disability of the adult, the second cause of dementia and the third cause of death in the industrialized countries, what constitutes à major public health issue. Stroke is characterized by a cerebral parenchymal lesion due to an isch…
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Your voice may reveal early dementia: new AI tool tested
Diagnosis CompletedMild Cognitive Impairment (MCI) is frequently underdiagnosed due to its subtle clinical presentation. This study evaluates the diagnostic performance of AcceXible, a speech analysis-based machine learning platform, compared to the Montreal Cognitive Assessment (MoCA) for MCI dete…
Sponsor: Accexible • Aim: Diagnosis
Last updated Jun 27, 2026 12:30 UTC
-
New drug candidate BL-M02D1 enters human trials for Hard-to-Treat cancers
Disease control OngoingIn phase Ia study, the safety and tolerability of BL-M02D1 in patients with locally advanced or metastatic triple negative breast cancer or other solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-M02D1. In phase I…
Phase: PHASE1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
CBD shows promise in curbing opioid cravings
Disease control CompletedThis research aims to determine the effects and safety of cannabidiol (CBD) (ATL5 softgel capsules) as an adjunctive therapy for patients who have Opioid Use Disorder and are taking buprenorphine + naloxone or methadone. Buprenorphine + naloxone and methadone is an approved treat…
Phase: PHASE2 • Sponsor: University of California, Los Angeles • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New eye drug shows promise for Diabetes-Related vision loss
Disease control CompletedThis is a multi-centered, open-labeled, single ascending-dose-cohort study to evaluate the safety and efficacy of 4 dose cohorts of AG-73305 administered by intravitreal injection in patients with diabetic macular edema (DME). The objectives of this study were to evaluate the sa…
Phase: PHASE2 • Sponsor: Allgenesis Biotherapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New combo aims to outsmart resistant lung cancer
Disease control Recruiting nowThe purpose of this study is to see if adding pirfenidone to atezolizumab will increase anti tumor activity and reduce treatment resistance in stage 4 and recurrent non- small cell lung cancer participants.
Phase: PHASE1, PHASE2 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug trial aims to halt Early-Stage blood cancer
Disease control Recruiting nowThis is a single-center, single arm, phase I study designed to determine the safety and find the recommended Phase 2 dose (RP2D) or maximum dose level (MTD) of Belantamab Mafodotin in patients with high-risk smoldering multiple myeloma. The study will have a dose-finding part and…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Simple drug may cut infection risk after major gut surgery
Disease control CompletedThis international, multicentre, pragmatic, double-blind, placebo-controlled, randomised trial of TxA versus placebo will enrol 3,300 patients throughout Australia and internationally. This is an effectiveness trial - some elements of the trial are deliberately left to the periop…
Phase: PHASE4 • Sponsor: Bayside Health • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New combo therapy aims to boost red blood cells in MDS patients
Disease control Recruiting nowStudy of the combination of luspatercept in low-risk myelodysplastic syndrom (LR-MDS) without ring sideroblasts (RS) having failed or being ineligible to ESA
Phase: PHASE1, PHASE2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for hemophilia b: trial tests Long-Acting clotting factor in chinese patients
Disease control CompletedThe study investigates how well the medicine called nonacog beta pegol (N9-GP) works in Chinese people with haemophilia B. Participants will be treated with N9-GP. This is a medicine that doctors can already prescribe in other countries. The medicine will be injected into a vein …
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Could freezing dangerous heart plaque stop a heart attack?
Disease control OngoingThe POLARSTAR study is an early safety and feasibility study to evaluate the performance and safety of the CryoTherapy System (CTS) for the treatment of coronary plaque lesions that are not obstructing blood flow but are at high-risk of rupture which would cause a major heart att…
Phase: NA • Sponsor: Cryotherapeutics SA • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Zapping cancer during surgery: new rectal cancer trial underway
Disease control OngoingSingle centre double-blinded three-arm randomised controlled trial of extended margin surgery + IOERT at standard dose (10 Gy) versus extended margin surgery + IOERT at higher dose (15 Gy) versus extended margin surgery alone in a 1:1:1 ratio in patients with Locally Advanced Rec…
Phase: NA • Sponsor: University Hospital Southampton NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New amputation technique may restore natural limb movement for amputees
Knowledge-focused OngoingThe agonist-antagonist myoneural interface (AMI) construct, known as the Ewing amputation at the trans-tibial level, has been shown to create a bi-directional neural communication platform as a means of controlling and interpreting proprioceptive feedback from a prosthetic joint.…
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jul 11, 2026 00:00 UTC
-
Intermittent fasting may cut cancer risk in obesity
Prevention OngoingApproximately 42% of American adults are obese, and this condition is strongly related to the development of colorectal cancer. Innovative lifestyle strategies to treat obesity and reduce colorectal cancer risk are critically needed. This research will demonstrate that time-restr…
Phase: NA • Sponsor: University of Illinois at Chicago • Aim: Prevention
Last updated Jul 23, 2026 00:00 UTC
-
New triple-drug combo shows promise for hard-to-treat leukemia patients
Disease control CompletedA study of siremadlin in combination with venetoclax plus azacitidine in adult participants with AML who are ineligible for chemotherapy. The primary purpose of this study was to assess whether siremadlin in combination with venetoclax plus azacitidine can enhance the clinical r…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC